Bipolar depression: Management options

CNS Drugs

Volumn 17, Issue 1, 2003, Pages 9-25

  Malhi, Gin S ^a,b   Mitchell, Philip B ^a,b   Salim, Shahzad ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; DESIPRAMINE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENELZINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

BEHAVIOR THERAPY; BIPOLAR DEPRESSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOMANIA; MANIA; MENTAL INSTABILITY; MIXED MANIA AND DEPRESSION; NEUROTRANSMISSION; ORGANIC PSYCHOSYNDROME; PRIORITY JOURNAL; PSYCHOTHERAPY; RASH; RATING SCALE; REVIEW; SEDATION; SEIZURE; SEROTONINERGIC NERVE CELL; SIDE EFFECT; SUICIDE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; WEIGHT GAIN;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 0037219091     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317010-00002     Document Type: Review

References (174)

1. Goodwin FK, Jamison KR, editors. Manic-depressive Illness. New York: Oxford University Press, 1990
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19
3. Keck Jr PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155 (5): 646-52
4. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: A meta-analysis. Br J Psychiatry 1997; 170: 205-28
5. Dilsaver SC, Chert YW, Swann AC. et al. Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994; 151: 1312-5
6. Strakowski SM, McElroy SL, Keck Jr PE, et al. Suicidality among patients with mixed and manic bipolar diorder. Am J Psychiatry 1996; 153: 674-6
7. Coppen A. Depression as a lethal disease: Prevention strategies. J Clin Psychiatry 1994; 55: 37-45
8. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar-manic depressive disorders. J Clin Psychiatry 1999; 60: 77-84
9. Turvey CL, Coryell WH, Arndt S, et al. Polarity sequence, depression, and chronicity in bipolar 1 disorder. J Nerv Ment Dis 1999; 187: 181-7
10. Dilsaver SC, Chen YW, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania, and pure mania. Psychiatr Res 1997; 73: 47-56
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington, DC: American Psychiatric Association, 1994
12. Leibenluft E, Suppes T. Treating bipolar illness: Focus on treatment algorithms and management of the sleep-wake cycle. Am J Psychiatry 1999; 156 (12): 1976-81
13. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-Depressive Association survey of bipolar members. J Affect Disord 1994; 31: 281-94
14. Sansone RA, Wiederman MW, Sansone LA, et al. An investigation of primary care patients receiving extended treatment with selective serotonin re-uptake inhibitors. Am J Manag Care 1998; 4: 1397-402
15. Roy-Byrne P, Post RM, Uhde TW, et al. The longitudinal course of recurrent affective illness: Life chart data from research patients at the NIMH. Acre Psychiatr Scand 1985; 317: 1-34
16. Mitchell PB, Wilhelm K, Parker G, et al. The clinical features of bipolar depression: A comparison with matched major depressive disorder patients. J Clin Psychiatry 2001; 62: 212-6
17. Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand 1966; 42: 1-188
18. Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986; 255: 3138-42
19. Coryell W, Scheftner W, Keller M, et al. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993; 150: 720-7
20. Compton MT, Nemeroff CB. The treatment of bipolar depression. J Clin Psychiatry 2000; 61 (9): 57-67
21. Malhi GS, Vieta E. Topics in contemporary psychiatric practice diagnosing bipolar disorder. Int J Psych Clin Pract 2001; 5 (3): 223-4
22. Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry 1996; 57: 24-30
23. McManus P, Mant A, Mitchell PB, et al. Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Med J Aust 2000; 173 (9): 458-61
24. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-22
25. Zornberg GL, Pope Jr HG. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol 1993; 13: 397-408
26. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158 (6): 906-12
27. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157 (1): 124-6
28. Simpson SG, DePaulo JR. Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol 1991; 11: 52-4
29. Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18 (6): 435-40
30. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000; 59: 225-9
31. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazadone for the treatment of major depression. J Clin Psychopharmacol 1994; 14: 170-9
32. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58: 532-7
33. Fabre LF, Brodie HKH, Graver D, et al. A multi-center evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry 1983; 44 (5): 88-94
34. Merideth CH, Feighner JP. The use of bupropion in hospitalized depressed patients. J Clin Psychiatry 1983; 44 (5): 85-7
35. Shopsin B. Bupropion's prophylactic efficacy in bipolar affective illness. J Clin Psychiatry 1983; 44 (5): 163-9
36. Wright G, Galloway L, Kim J, et al. Bupropion in the long-term treatment of cyclic mood disorders: Mood stabilizing effects. J Clin Psychiatry 1985; 46: 22-5
37. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar 2 patients. J Clin Psychiatry 1990; 51: 450-5
38. Brown ES, Dilsaver SC, Shoaib AM, et al. Depressive mania: Response of residual depression to bupropion. Biol Psychiatry 1994: 35: 493-4
39. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (4): 4-50
40. Sachs GS, Lafer B, Stoll AL, et al. A double blind trial of bupropion versus desipramine for bipolar depression. Am J Psychiatry 1994; 55: 910-9
41. Fogelson DL, Bystritsky A, Panau R. Bupropion in the treatment of bipolar disorders: The same old story? J Clin Psychiatry 1992; 53: 443-6
42. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59 (7): 366-73
43. Quitkin FM, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with or without imipramine for bipolar 1 patients. Arch Gen Psychiatry 1981; 38: 902-7
44. Baumhackl U, Biziere K, Fischbach R, et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorders. Br J Psychiatry 1989; 155: 78-83
45. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-6
46. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression. Am J Psychiatry 1992; 149: 195-8
47. Croughan J, Secunda SK, Katz MM, et al. Sociodemographic and prior clinical course characteristics associated with treatment response in depressed patients. J Psychiatr Res 1988; 22: 227-37
48. Prien RF, Klett CJ, Caffey Jr EM. Lithium carbonate and imipramine in prevention of affective episodes: A comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420-5
49. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in prevention of recurrences in unipolar and bipolar affective disorders: Report of NIMH Collaborative Study Group comparing lithium carbonate, imipramine and lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096-104
50. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144: 1403-11
51. Peel M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-50
52. Koukopoulos A, Reginaldi D, Laddomada P, et al. Course of manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharakol 1980; 13: 156-67
53. Frances A, Docherty JP, Kahn DA. The expert consensus guideline series: Treatment of bipolar disorder. J Clin Psychiatry 1996; 57: 1-88
54. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 1982; 170: 628-34
55. Himmelhoch JM, Detre T, Kupfer DJ, et al. Treatment of previously intractable depression with tranylcypromine and lithium. J Nerv Ment Dis 1972; 155: 216-20
56. Himmelhoch JM. Social anxiety, hypomania and the bipolar spectrum: Data, theory and clinical issues. J Affect Disord 1998; 50: 203-13
57. Mallinger AG, Frank E, Barwell MM, et al. Effectiveness of traditional antidepressants is suboptimal in the depressed phase of bipolar disorder [poster #69]. The Annual Meeting of the New Clinical Drug Evaluation Unit Program; 1999 Jun 1-4; Boca Raton, 114-5
58. Nolen WA, Van de Putte JJ, Dijken WA, et al. Treatment strategy in depression: I. Nontricyclic and selective reuptake inhibitors in resistant depression: A double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988; 78: 668-75
59. Larsen JK. MAOIs in the treatment of depression: A review. Eur J Psychiatry 1991; 5: 79-88
60. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993; 163: 30-4
61. Thase ME, Trivedi MH, Rush AJ, et al. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12 (3): 185-219
62. Ketter TA, Post RM, Parekh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: Preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry 1995; 56: 471-5
63. Lotufo-Neto F, Trivedi M, Thase ME. Metaanalysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine in the treatment of depression. Neuropsychopharmacology 1999; 20: 226-47
64. Silverstone T. Moclobemide vs. imipramine in bipolar depression: A multicenter double-blind clinical trial. Acta Psychiatr Scand 2001; 104: 104-9
65. Angst J, Stabl M. Efficacy of moclobemide in different patient groups: A meta-analysis of studies. Psychopharmacology 1992; 106: 109-13
66. Thase ME, Sachs GS. Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000; 48 (6): 558-72
67. Vink J, Nolen WA, Verbraak M. Is moclobemide bij therapieresistente depressie een alternatief voor tranylcypromine? Enige ervaringen. Tijdschr Psychiatrie 1994; 36: 639-46
68. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995; 152 (8): 1130-8
69. Calabrese JR, Rapport DJ, Kimmel SE, et al. Controlled trials in bipolar I depression: Focus on switch rates and efficacy. Eur Neuropsychopharmacol 1999; 9 (4): 109-12
70. Frye MA, Denicoff KD, Bryan AL, et al. Association between low serum free T4 and greater mood instability and depression in lithium maintained bipolar patients. Am J Psychiatry 1999; 156 (12): 1909-14
71. Dilsaver SC, Swann AC. Mixed mania: Apparent induction by a tricyclic antidepressant in five consecutively treated patients with bipolar depression. Biol Psychiatry 1995; 37: 60-2
72. Boerlin HL, Gitlin MJ, Zoellner LA, et al. Bipolar depression and antidepressant-induced mania: A naturalistic study. J Clin Psychiatry 1998; 59 (7): 374-81
73. Bottlender R, Rudolf D, Strauss A, et al. Antidepressant associated maniform states in acute treatment of patients with bipolar 1 depression. Eur Arch Psychiatry Clin Neurosci 1998; 248: 296-300
74. Lewis JL, Winokur G. The induction of mania: A natural history study with controls. Arch Gen Psychiatry 1982; 39: 303-6
75. Rouillon F, Lejoyeux M, Filteau MJ. Unwanted effects of long term treatment. In: Montgomery SA, Rouillon FA, editors. Long Term Treatment of Depression. New York: Wiley, 1992
76. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar 2 major depressive episode. J Clin Psychopharmacol 1998; 18 (5): 414-7
77. Silverstone T. A double-blind multicentre trial of moclobemide vs. imipramine in bipolar depression. Ear Neuropsychopharmacol 1997; 7: 169-70
78. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-36
79. Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. J Clin Psychiatry 1998; 59: 1-9
80. Bowden CL. New concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998; 19: 194-9
81. Fieve RR, Platman SR, Plutchik RR. The use of lithium in affective disorders. I: Acute endogenous depression. Am J Psychiatry 1968; 125: 79-83
82. Goodwin FK, Murphy DL, Bunney WE. Lithium carbonate treatment in depression and mania. Arch Gen Psychiatry 1969; 21: 486-96
83. Greenspan K, Schildkraut JJ, Gordon EK, et al. Catecholamine metabolism in affective disorders: III. J Psychiatr Res 1970; 7: 171-82
84. Stokes PE, Stoll PM, Shamoian CA, et al. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; I: 1319-25
85. Goodwin FK, Murphy DL, Dunner DL, et al. Lithium response in unipolar versus bipolar depression. Am J Psychiatry 1972; 129: 76-9
86. Noyes R, Dempsey GM, Blum A, et al. Lithium treatment of depression. Compr Psychiatry 1974; 15: 187-93
87. Mendels J. Lithium in the treatment of depression. Am J Psychiatry 1976; 4: 373-8
88. Baron M, Gershon ES, Rudy V, et al. Lithium carbonate response in depression. Arch Gen Psychiatry 1975; 32: 1107-11
89. Donnelly EF, Goodwin FK, Waldman IN, et al. Prediction of antidepressant responses to lithium. Am J Psychiatry 1978; 135: 552-6
90. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-8
91. Ebert D, Jaspert A, Murata H, et al. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients. Psychopharmacology 1995; 118: 223-5
92. Heit F, Nemeroff CB. Lithium augmentation of antidepressants in treatment-refractory depression. J Clin Psychiatry 1998; 59: 28-33
93. Muller-Oerlinghausen B, Berghofer A. Antidepressants suicidal risk. J Clin Psychiatry 1999; 60: 94-9
94. Franchini L, Zanardi R, Gasperini M, et al. Fluvoxamine and lithium in long-term of unipolar subjects with high recurrence rate. J Affect Disord 1996; 38: 67-9
95. Swann AC, Bowden CL, Morris D, et al. Depression during mania: Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54 (1): 37-42
96. Dunner DL, Patrick V, Fieve RR. Rapid cycling manic depressive patients. Compr Psychiatry 1977; 18: 561-6
97. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry 1980; 137: 782-90
98. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29-34
99. Post RM, Leverich GS, Denicoff KD, et al. Alternative approaches to refractory depression in bipolar illness. Depress Anxiety 1997; 5: 73-83
100. Dilsaver SC, Swann SC, Chen Y, et al. Treatment of bipolar depression with carbamazepine: Results of an open study. Biol Psychiatry 1996; 40: 935-7
101. Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Arch Gen Psychiatry 1989; 46: 794-800
102. Post RM, Ketter TA, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology 1996; 128: 115-29
103. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-8
104. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium vs. carbamazepine in the maintenance treatment of bipolar disorders: A randomized study. J Affect Disord 1997; 43: 151-61
105. Calabrese JR, Markovitz PJ, Kimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12: 53S-6S
106. Petty F, Trivedi MH, Fulton M, et al. Benzodiazepines as antidepressants: Does GABA play a role in depression? Biol Psychiatry 1995; 38: 578-91
107. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271 (12): 918-24
108. McElroy SL, Keck Jr PE, Pope Jr HG, et al. Valproate in psychiatric disorders: Literature review and clinical guidelines. J Clin Psychiatry 1989; 50 (3): 23-9
109. McElroy SL, Keck Jr PE. Treatment guidelines for valproate in bipolar, schizoaffective disorders. Can J Psychiatry 1993; 38: 62-6
110. Winsberg ME, DeGolia SG, Strong CM, et al. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67 (1-3): 207-12
111. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57 (5): 481-9
112. Kusumaker V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72: 145-8
113. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17 (3): 185-9
114. Bowden CL, Mitchell P, Suppes T, et al. Lamotrigine in the treatment of bipolar depression. Eur Neuropsychopharmacol 1999; 9 (4): 113-7
115. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar 1 depression. J Clin Psychiatry 1999; 60: 79-88
116. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20 (6): 607-14
117. Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001; 10 (4): 661-915
118. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Revista Psiquiatr Clin 2001; 28 (4): 215
119. Messenheimer J, Mullens EL, Giorgi L, et al. Safety of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18: 181-296
120. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy: Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000; 2: 249-55
121. Macdonald KJ, Young LT. Newer antiepileptic drugs in bipolar disorder: Rationale for use and role in therapy. CNS Drugs 2002; 16 (8): 549-62
122. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430-6
123. Parker G, Roy K, Hadzi-Pavlovic D, et al. Psychotic (delusional) depression: A meta-analysis of physical treatments. J Affect Disord 1992; 24 (1): 17-24
124. Parker G, Malhi G. Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry 2001; 35 (5): 631-8
125. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156: 702-9
126. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine I acute bipolar mania: A double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841-9
127. Sanger TM, Grundy SL, Gibson PJ, et al. Long term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study. J Clin Psychiatry 2001; 62: 273-81
128. Frazier JA, Meyer MC, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999: 38: 960-5
129. Ghaemi SN, Sachs GS, Baldassano C, et al. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry 1997; 42: 196-9
130. Ghaemi SN, Sachs GS. Long-term risperidone treatment in bipolar disorder: 6-Month follow up. Int Clin Psychopharmacol 1997; 12: 333-8
131. Keck Jr PE, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizo-affective disorder, and psychotic mood disorders. J Clin Psychiatry 1995; 56: 466-70
132. Lane HY, Chang WH. Risperidone monotherapy for psychotic depression unresponsive to other treatments [letter]. J Clin Psychiatry 1998; 59: 624
133. O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression [letter]. J Clin Psychopharmacol 1998; 18: 89-91
134. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256-9
135. Welner M. Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis [letter]. J Clin Psychopharmacol 1996; 16: 460-1
136. Ghaemi SN. On defining 'mood stabilizer'. Bipolar Disord 2001; 3 (3): 154-8
137. Shelton RC. Mood-stabilizing drugs in depression. J Clin Psychiatry 1999; 60: 37-40
138. Suppes T, Webb A, Paul B, et al. Clinical outcomes in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-9
139. Malhi GS, Mitchell PB, Caterson I. Why getting fat, Doc? Weight gain and psychotropic medications. Aust N Z J Psychiatry 2001; 35 (3): 315-21
140. Daly JJ, Prudic J, Devanand DP, et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 2001; 3 (2): 95-104
141. Prudic J, Sackeim H, Devanand DP. Medication resistance and clinical response to ECT. Psychiatry Res 1990; 31: 287-96
142. Stahl S, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatrica Scand 1997; 391: 22-30
143. Berzewski H, Van Moffaert M, et al. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997; 1: 37-47
144. Davis R, Whittington R, Bryson HM. Nefazodone: A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997; 53: 608-36
145. Yatham LN, Kusumakar V, Parikh SV, et al. Bipolar depression: Treatment options. Can J Psychiatry 1997; 42: 87-91
146. Bauer M, Zaninelli R, Muller-Oerlinghausen B, et al. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: A double-blind study. J Clin Psychopharmacol 1999; 19: 164-71
147. Frances AJ, Kahn DA, Carpenter D, et al. The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1998; 59 (4): 73-9
148. Clarkin JF, Glick ID, Haas GL, et al. A randomized clinical trial of inpatient family intervention. C: Results for affective disorders. J Affect Disord 1990; 18: 17-28
149. Clarkin JF, Carpenter D, Hull J, et al. Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatr Serv 1998; 49: 531-3
150. Haas GL, Glick ID, Clarkin JF, et al. Inpatient family intervention: A randomized clinical trial. II: Results at hospital discharge. Arch Gen Psychiatry 1988; 45: 217-24
151. Miklowitz DJ, Goldstein MJ, Nuechterlein KH, et al. Family factors and the course of bipolar affective disorder. Arch Gen Psychiatry 1988; 45: 225-31
152. Peet M, Harvey NS. Lithium maintenance. 1: A standard education programme for patients. Br J Psychiatry 1991; 158: 197-200
153. Perry A, Tarrier N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999; 318: 149-53
154. Miklowitz DJ, Dimoneau TL, George EA. Family focused treatment of bipolar disorder: 1-Year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000; 48: 582-92
155. Cochran SD. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol 1984; 52: 873-8
156. Zaretsky AE, Segal ZV, Gemar M. Cognitive therapy for bipolar depression: A pilot study. Can J Psych 1999; 44 (5): 491-4
157. Frank E, Swartz HA, Mallinger AG, et al. Adjunctive psychotherapy for bipolar disorder: Effects of changing treatment modality. J Abnorm Psychol 1999; 108: 579-87
158. Calabrese JR, Delucchi GA. Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989; 50 (3): 30-4
159. Bottlender R, Rudolf D, Straub A. Mood-stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar 1 depressed patients. J Affect Disord 2001; 63: 79-83
160. Feighner JP, Gardner EA, Johnston A, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991; 52: 329-35
161. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57: 503-9
162. Potter WZ. Bipolar depression: Specific treatments. J Clin Psychiatry 1998; 59 (18): 30-6
163. Srisurapanont M, Yatham LN, Zis A. Treatment of acute bipolar depression: A review of the literature. Can J Psychiatry 1995; 40: 533-44
164. Moller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000; 250 (2): 57-68
165. Altshuler L, Kiriakos L, Calcagno J, et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: A retrospective chart review. J Clin Psychiatry 2001; 62: 612-6
166. Sackeim GA, Rush AJ. Melancholia and response to ECT. Am J Psychiatry 1995; 152: 1242-3
167. American Psychiatric Association. Practice guideline for the patients with bipolar disorder. Am J Psychiatry 2001; 151 (12): 1-36
168. Wheeler Vega JA, Mortimer AM, Tyson PJ. Somatic treatment of psychotic depression: Review and recommendations for practice. J Clin Psychopharmacol 2000; 20 (5): 504-19
169. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32: 241-51
170. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: A meta-analysis. Arch Gen Psychiatry 1996; 53: 842-8
171. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. 2: Treatment of refractory rapid cycling with high dose levothyroxine: A preliminary study. Arch Gen Psychiatry 1990; 47: 435-40
172. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium maintenance treatment of depression and mania in bipolar 1 and bipolar 2 disorders. Am J Psychiatry 1998; 155 (5): 638-45
173. Ghaemi SN, Cherry EL, Katzow JA, et al. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord 2000; 2: 196-9
174. Mitchell PB, Malhi GS. The expanding pharmacopoeia for bipolar disorder. Annu Rev Med 2002; 53: 173-88